Pharma: Clinic Roundup
Friday, March 30, 2012
Eli Lilly and Co. Inc., of Indianapolis, published new Phase II data in The New England Journal of Medicine showing that ixekizumab (LY2439821), an anti-IL-17 monoclonal antibody, met its primary endpoint of achieving at least a 75 percent improvement in psoriasis area and severity index (PASI) scores from baseline. The study enrolled 142 subjects, and significantly more patients achieved a PASI response in the 150-mg, 75-mg and 25-mg group (82 percent, 83 percent and 77 percent) than the placebo group (8 percent). The 10-mg dose group did not separate from placebo.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.